Epigenomics (XTRA:ECX) Stock Price & Quote Analysis

ECX fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

ECX Stock Overview

Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer.

Rewards

Revenue is forecast to grow 43.39% per year

Earnings have grown 6.2% per year over the past 5 years

Risk Analysis

Earnings are forecast to decline by an average of 11.3% per year for the next 3 years

Does not have a meaningful market cap (€8M)

Currently unprofitable and not forecast to become profitable over the next 3 years

Volatile share price over the past 3 months

+ 1 more risk

Epigenomics AG Competitors

4SC

XTRA:VSCA

€30.5m

co.don

XTRA:CNW

€15.5m

2invest

XTRA:2INV

€53.6m

Paion

XTRA:PA8

€66.9m

Price History & Performance

Summary of all time highs, changes and price drops for Epigenomics
Historical stock prices
Current Share Price	€0.47
52 Week High	€1.34
52 Week Low	€0.38
Beta	1.17
1 Month Change	2.62%
3 Month Change	-5.81%
1 Year Change	-59.97%
3 Year Change	-96.49%
5 Year Change	-98.58%
Change since IPO	-98.38%

Shareholder Returns

	ECX	DE Biotechs	DE Market
7D	11.9%	-2.1%	0.6%
1Y	-60.0%	-4.1%	-20.0%

Return vs Industry: ECX underperformed the German Biotechs industry which returned -3% over the past year.

Return vs Market: ECX underperformed the German Market which returned -20.8% over the past year.

Price Volatility

Is ECX's price volatile compared to industry and market?
ECX volatility
ECX Average Weekly Movement	9.1%
Biotechs Industry Average Movement	8.7%
Market Average Movement	5.6%
10% most volatile stocks in DE Market	10.4%
10% least volatile stocks in DE Market	2.8%

Stable Share Price: ECX is more volatile than 75% of German stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: ECX's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

Founded	Employees	CEO	Website
1998	35	Greg Hamilton	https://www.epigenomics.com

Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer in the United States, Europe, and China. The company’s products also include hepatocellular carcinoma blood test; Epi proColon, a liquid biopsy test for detection of colorectal cancer; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA.

Epigenomics AG Fundamentals Summary

How do Epigenomics's earnings and revenue compare to its market cap?
ECX fundamental statistics
Market Cap	€7.51m
Earnings (TTM)	-€3.88m
Revenue (TTM)	€6.21m

1.2x

P/S Ratio

-1.9x

P/E Ratio

Is ECX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
ECX income statement (TTM)
Revenue	€6.21m
Cost of Revenue	€139.00k
Gross Profit	€6.07m
Other Expenses	€9.96m
Earnings	-€3.88m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

Aug 10, 2022

Earnings per share (EPS)	-0.24
Gross Margin	97.76%
Net Profit Margin	-62.52%
Debt/Equity Ratio	0%

How did ECX perform over the long term?

See historical performance and comparison

Epigenomics XTRA:ECX Stock Report

Last Price

Market Cap

7D

1Y

Updated

Data